Tumor specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia

G. E. Brannen, D. S. Coffey

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty patients were skin tested with solubilized components of autologous prostatic adenocarcinoma or benign prostatic hypertrophy (BPH). Four of 10 patients bearing adenocarcinoma of the prostate exhibited tumor-specific cutaneous responsiveness to solubilized autologous tumor-specific antigens (TSA). One responding patient also responded to solubilized allogeneic TSA. A single patient bearing prostatic carcinoma responded only to solubilized components of allogeneic BPH. Nine of 10 patients with BPH exhibited no response to solubilized components of autologous BPH. The patient responding to the extract of autologous BPH, however, also had clinical stage B adenocarcinoma of the prostate. These observations suggest host responsiveness to TSA of prostatic carcinoma. Possible clinical significance and mechanisms to explain the findings are discussed.

Original languageEnglish (US)
Pages (from-to)211-216
Number of pages6
JournalCancer treatment reports
Volume61
Issue number2
StatePublished - Dec 1 1977

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tumor specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia'. Together they form a unique fingerprint.

Cite this